Intravenous Busulfan Plus Melphalan Is a Highly Effective, Well-Tolerated Preparative Regimen for Autologous Stem Cell Transplantation in Patients with.

Slides:



Advertisements
Similar presentations
Outcomes of Adults with Acute Lymphoblastic Leukemia Relapsing after Allogeneic Hematopoietic Stem Cell Transplantation  Li Mei Poon, Amir Hamdi, Rima.
Advertisements

Allogeneic Stem Cell Transplantation (Allo-SCT) for the Treatment of T-Cell Acute Lymphoblastic Leukemia (T-ALL); Evaluation of Minimal Residual Disease.
High-Dose Chemotherapy and Autologous Stem Cell Transplantation for Primary Central Nervous System Lymphoma (PCNSL) in First Complete Remission (CR1) 
Outcomes of Adults with Acute Lymphoblastic Leukemia Relapsing after Allogeneic Hematopoietic Stem Cell Transplantation  Li Mei Poon, Amir Hamdi, Rima.
Outcome of Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Low Left Ventricular Ejection Fraction  Muzaffar H. Qazilbash, Ali Imran.
The use of high-dose cyclophosphamide, carmustine, and thiotepa plus autologous hematopoietic stem cell transplantation as consolidation therapy for high-risk.
In Stem Cell Transplantation by Limiting the Morbidity of Graft-versus-Host Disease Tolerance to Myeloablative Conditioning is Improved  Nicolas Novitzky,
Muzaffar H. Qazilbash, MD, Peter Thall, PhD, Patricia S
High-Dose Infusional Gemcitabine Combined with Busulfan and Melphalan with Autologous Stem-Cell Transplantation in Patients with Refractory Lymphoid.
The Effect of Statin Use at the Time of Autologous Transplant on Response and Survival in Multiple Myeloma  Mehdi Hamadani, Erinn Hade, Don M. Benson,
Clofarabine ± Fludarabine with Once Daily i. v
Outcome of Patients with Multiple Myeloma by Ethnicity in the Setting of Autologous Stem Cell Transplant  Koji Sasaki, MD, Qaiser Bashir, MD, Nina Shah,
Moderate Renal Function Impairment Does Not Affect Outcomes of Reduced-Intensity Conditioning with Fludarabine and Melphalan for Allogeneic Hematopoietic.
T-Cell Acute Lymphoblastic Lymphoma (T-LBL) and Stem Cell Transplantation (SCT): A Comparison of Outcomes with T-Cell Acute Lymphoblastic Leukemia (T-ALL) 
Clinical Outcomes of Multiple Myeloma Patients with TP53 Gene Deletion after Autologous Stem Cell Transplantation: The MD Anderson Cancer Center Experience 
Long-Term Outcomes of Autologous Stem Cell Transplantation for Follicular Non- Hodgkin Lymphoma: Effect of Histological Grade and Follicular International.
Results of a Retrospective Single Institution Analysis of Targeted Skeletal Radiotherapy with 166Holmium-DOTMP as Conditioning Regimen for Autologous.
Mixed T Lymphocyte Chimerism after Allogeneic Hematopoietic Transplantation Is Predictive for Relapse of Acute Myeloid Leukemia and Myelodysplastic Syndromes 
Long-Term Follow-Up of Patients Who Experienced Graft Failure Postallogeneic Progenitor Cell Transplantation. Results of a Single Institution Analysis 
Intravenous Busulfan Plus Melphalan Is a Highly Effective, Well-Tolerated Preparative Regimen for Autologous Stem Cell Transplantation in Patients with.
Outcomes of Patients with Myeloid Malignancies Treated with Allogeneic Hematopoietic Stem Cell Transplantation from Matched Unrelated Donors Compared.
Autologous Hematopoietic Stem Cell Transplantation May Reverse Renal Failure in Patients with Multiple Myeloma  Gaurav C. Parikh, Ali Imran Amjad, Rima.
Allogeneic Stem Cell Transplantation (Allo-SCT) for the Treatment of T-Cell Acute Lymphoblastic Leukemia (T-ALL); Evaluation of Minimal Residual Disease.
Significance of Persistent Cytogenetic Abnormalities on Myeloablative Allogeneic Stem Cell Transplantation in First Complete Remission  Betul Oran, Uday.
Phase II study of autologous transplantation with interleukin-2-incubated peripheral blood stem cells and posttransplantation interleukin-2 in relapsed.
Similar Transplantation Outcomes for Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients with Haploidentical versus 10/10 Human Leukocyte Antigen–
Impact of Hepatitis B Core Antibody Seropositivity on the Outcome of Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma  Ankur Varma,
Pure Red Cell Aplasia in Major ABO-Mismatched Allogeneic Hematopoietic Stem Cell Transplantation Is Associated with Severe Pancytopenia  Fleur M. Aung,
Phase II Trial of Graft-versus-Host Disease Prophylaxis with Post-Transplantation Cyclophosphamide after Reduced-Intensity Busulfan/Fludarabine Conditioning.
The International Prognostic Index Assessed at Relapse Predicts Outcomes of Autologous Transplantation for Diffuse Large-Cell Non-Hodgkin’s Lymphoma in.
Long-Term Follow-up of Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia:
Intravenous Busulfan and Melphalan as a Conditioning Regimen for Autologous Stem Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma:
Phase I and pharmacokinetic study of docetaxel combined with melphalan and carboplatin, with autologous hematopoietic progenitor cell support, in patients.
Outcomes of Patients 65 Years and Older with Non-Hodgkin Lymphoma Receiving Reduced-Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplantation.
The Development of a Myeloablative, Reduced-Toxicity, Conditioning Regimen for Cord Blood Transplantation  Rohtesh S. Mehta, Antonio Di Stasi, Borje S.
Improved Outcomes in Intermediate- and High-Risk Aggressive Non-Hodgkin Lymphoma after Autologous Hematopoietic Stem Cell Transplantation Substituting.
Kamal Kant Singh Abbi, Junting Zheng, Sean M
Efficacy of Thiotepa-Busulfan-Cyclophosphamide (TBC) Conditioning and Autologous Transplantation As Consolidation for Systemic Non-Hodgkin Lymphoma with.
A Phase III Study of Infliximab and Corticosteroids for the Initial Treatment of Acute Graft-versus-Host Disease  Daniel R. Couriel, Rima Saliba, Marcos.
Impact of t(11;14)(q13;q32) on the Outcome of Autologous Hematopoietic Cell Transplantation in Multiple Myeloma  Koji Sasaki, Gary Lu, Rima M. Saliba,
Age and Modified European LeukemiaNet Classification to Predict Transplant Outcomes: An Integrated Approach for Acute Myelogenous Leukemia Patients Undergoing.
Outcome of Patients with Multiple Myeloma with t(4;14) after Autologous Hematopoietic Stem Cell Transplantation  Koji Sasaki, MD, Rima Saliba, PhD, Gary.
Biology of Blood and Marrow Transplantation
Clofarabine Plus Busulfan is an Effective Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Acute Lymphoblastic.
Results of 10-Year Single Center Experience with Pharmacokinetics Directed Intravenous Busulfan, Cyclophosphamide and Etoposide Preparative Regimen in.
Haploidentical Transplantation for Advanced Hematologic Malignancies Using Melphalan-Based Conditioning – Mature Results from a Single Center  Sai Ravi.
Adverse Prognostic Factors for Morbidity and Mortality During Peripheral Blood Stem Cell Mobilization in Patients with Light Chain Amyloidosis  Jason.
Vorinostat Combined with High-Dose Gemcitabine, Busulfan, and Melphalan with Autologous Stem Cell Transplantation in Patients with Refractory Lymphomas 
Dose Intensification of Busulfan in the Preparative Regimen Is Associated with Improved Outcomes: A Phase I/II Controlled, Randomized Study  Simrit Parmar,
Resolved Hepatitis B Virus Infection Is Not Associated with Worse Outcome after Allogeneic Hematopoietic Stem Cell Transplantation  Carlos A. Ramos, Rima.
Myeloablative Reduced-Toxicity i. v
Prognostic factors for outcomes of patients with refractory or relapsed acute myelogenous leukemia or myelodysplastic syndromes undergoing allogeneic.
Cytogenetics and Blast Count Determine Transplant Outcomes in Advanced AML  Uday R. Popat, MD, Rima Saliba, PhD, Betul Oran, MD, Julianne Chen, BS, Amin.
Comparison of High-Dose Gemcitabine, Busulfan and Melphalan (GEM/BU/MEL) and BEAM in Concurrent Patient Cohorts with Mature T-CELL NON-Hodgkin's Lymphoma.
Allogeneic Stem Cell Transplantation for Myelofibrosis with Leukemic Transformation  Stefan O. Ciurea, Marcos de Lima, Sergio Giralt, Rima Saliba, Carlos.
Prognostic significance of occult tumor cells in the apheresis products of patients with advanced breast cancer receiving high-dose chemotherapy and autologous.
Early Post-Transplant Minimal Residual Disease Assessment Improves Risk Stratification in Acute Myeloid Leukemia Patients  Mithun Vinod Shah, Rima M.
Outcomes of Haploidentical Stem Cell Transplantation for Lymphoma with Melphalan- Based Conditioning  Jonathan E. Brammer, Issa Khouri, Sameh Gaballa,
Muzaffar H. Qazilbash, Rima M
Dose Intensification of Busulfan in the Preparative Regimen is Associated with Improved Survival: A Phase I/II Controlled, Randomized Study  Simrit Parmar,
Long-term Outcome of Hodgkin Disease Patients Following High-Dose Busulfan, Etoposide, Cyclophosphamide, and Autologous Stem Cell Transplantation—A Similar.
Improved Early Outcomes Using a T Cell Replete Graft Compared with T Cell Depleted Haploidentical Hematopoietic Stem Cell Transplantation  Stefan O. Ciurea,
Autologous Stem Cell Transplantation for Refractory or Poor-Risk Relapsed Hodgkin's Lymphoma: Effect of the Specific High-Dose Chemotherapy Regimen on Outcome 
Clinical Outcome following Autologous and Allogeneic Blood and Marrow Transplantation for Relapsed Diffuse Large-Cell Non-Hodgkin’s Lymphoma  Ivan Aksentijevich,
Futility of Relapsed Diffuse Large B Cell Lymphoma Transplantation?
Daniel Couriel, Chitra Hosing, Rima Saliba, Elizabeth J
Phase II Trial of High-Dose Gemcitabine/Busulfan/Melphalan with Autologous Stem Cell Transplantation for Primary Refractory or Poor-Risk Relapsed Hodgkin.
Maintenance Therapy with Low-Dose Azacitidine (AZA) after Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) for Relapsed or Refractory AML or MDS:
Once Daily i. v. Busulfan and Fludarabine (i. v
Results of Allogeneic Double Umbilical Cord Blood Transplantation for Relapsed and Refractory Hodgkin Lymphoma  Philip A. Thompson, MBBS, FRACP, FRCPA,
Presentation transcript:

Intravenous Busulfan Plus Melphalan Is a Highly Effective, Well-Tolerated Preparative Regimen for Autologous Stem Cell Transplantation in Patients with Advanced Lymphoid Malignancies  Partow Kebriaei, Timothy Madden, Reza Kazerooni, Xuemei Wang, Peter F. Thall, Celina Ledesma, Yago Nieto, Elizabeth J. Shpall, Chitra Hosing, Muzaffar Qazilbash, Uday Popat, Issa Khouri, Richard E. Champlin, Roy B. Jones, Borje S. Andersson  Biology of Blood and Marrow Transplantation  Volume 17, Issue 3, Pages 412-420 (March 2011) DOI: 10.1016/j.bbmt.2010.07.016 Copyright © 2011 Terms and Conditions

Figure 1 Overall survival (OS) and progression-free survival (PFS) for patients with Hodgkin lymphoma. Sensitivity to chemotherapy does not significantly affect outcome. Biology of Blood and Marrow Transplantation 2011 17, 412-420DOI: (10.1016/j.bbmt.2010.07.016) Copyright © 2011 Terms and Conditions

Figure 2 OS and PFS for patients with non-Hodgkin lymphoma. Sensitivity to chemotherapy does not have a significant impact on outcome. Biology of Blood and Marrow Transplantation 2011 17, 412-420DOI: (10.1016/j.bbmt.2010.07.016) Copyright © 2011 Terms and Conditions

Figure 3 OS and PFS for patients with multiple myeloma (MM). Sensitivity to chemotherapy does not significantly affect outcome. Biology of Blood and Marrow Transplantation 2011 17, 412-420DOI: (10.1016/j.bbmt.2010.07.016) Copyright © 2011 Terms and Conditions

Feedback: Privacy Policy Feedback
Do Not Sell My Personal Information
About project: SlidePlayer Terms of Service

© 2024 SlidePlayer.com Inc. All rights reserved.